IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect

Multiple myeloma (MM) patients who receive killer cell Ig–like receptor (KIR) ligand–mismatched, T cell–depleted, allogeneic transplantation may have a reduced risk of relapse compared with patients who receive KIR ligand–matched grafts, suggesting the importance of this signaling axis in the natura...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Benson, Don M., Bakan, Courtney E., Zhang, Shuhong, Collins, Shauna M., Liang, Jing, Srivastava, Shivani, Hofmeister, Craig C., Efebera, Yvonne, Andre, Pascale, Romagne, Francois, Bléry, Mathieu, Bonnafous, Cécile, Zhang, Jianying, Clever, David, Caligiuri, Michael A., Farag, Sherif S.
Format: Artigo
Sprache:Inglês
Veröffentlicht: American Society of Hematology 2011
Schlagworte:
Immunobiology
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3490103/
https://ncbi.nlm.nih.gov/pubmed/22031859
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2011-06-360255
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge